Transcode Therapeutics (RNAZ) closed at $1.67 on October 27, 2026, down 2.1% from the previous close, on volume of 7,497 shares (30-day average 47,133).
Data as of October 27, 2026.
TransCode Therapeutics Presents Phase 1a Clinical Data for TTX-MC138 at ESMO Congress 2026
PRNewswire (Mon, 26-Oct 7:31 AM ET)
TransCode Therapeutics to Present Phase 1a Clinical Trial Data for TTX-MC138 at ESMO Congress 2026
PRNewswire (Mon, 19-Oct 8:05 AM ET)
Natera and TransCode Therapeutics to Collaborate on Phase 2a Trial of TTX-MC138 in Colorectal Cancer
Business Wire (Tue, 13-Oct 7:30 AM ET)
PRNewswire (Mon, 28-Sep 8:05 AM ET)
PRNewswire (Tue, 22-Sep 8:04 AM ET)
TransCode Therapeutics Announces Leadership Transition
PRNewswire (Thu, 10-Sep 4:10 PM ET)
PRNewswire (Mon, 31-Aug 8:05 AM ET)
Market Chameleon (Tue, 6-Jan 3:36 AM ET)
Market Chameleon (Wed, 8-Oct 6:50 AM ET)
TransCode Therapeutics' Stock Surges 45.2% on Positive Clinical Trial News
Market Chameleon (Thu, 6-Feb 3:31 AM ET)
TransCode Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of RNA-based therapeutics and immuno-oncology treatments for cancer. The company's lead candidate, TTX-MC138, targets microRNA-10b and has completed a Phase 1a clinical trial, while it is also advancing additional product candidates, including a cancer vaccine and an oncolytic immunotherapy platform.
Transcode Therapeutics trades on the NASDAQ stock market under the symbol RNAZ.
As of October 28, 2026, RNAZ stock price climbed to $1.71 with 3,637 million shares trading.
RNAZ has a beta of 0.74, meaning it tends to be less sensitive to market movements. RNAZ has a correlation of 0.01 to the broad based SPY ETF.
RNAZ has a market cap of $1.81 million. This is considered a Sub-Micro Cap stock.
In the last 3 years, RNAZ traded as high as $17,947.79 and as low as $1.52.
The top ETF exchange traded funds that RNAZ belongs to (by Net Assets): VXF.
RNAZ has underperformed the market in the last year with a return of -87.0%, while the SPY ETF gained +13.6%. In the last 3 month period, RNAZ fell short of the market, returning -68.6%, while SPY returned +4.6%. However, in the most recent 2 weeks RNAZ has outperformed the stock market by returning +1.8%, while SPY returned -0.9%.
RNAZ support price is $1.52 and resistance is $1.82 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that RNAZ shares will trade within this expected range on the day.
